Altered phenytoin clearance during intensive chemotherapy for acute lymphoblastic leukemia.
Jarosinski
P F
PF
Pharmacy Department, Warren G. Magnuson Clinical Center, National Cancer Institute, Bethesda, MD 20892.
Moscow
J A
JA
Alexander
M S
MS
Lesko
L J
LJ
Balis
F M
FM
Poplack
D G
DG
D000971:Antineoplastic Combined Chemotherapy Protocols; D002648:Child; D004827:Epilepsy / Q000150:complications / Q000188:drug therapy; D006801:Humans; D007945:Leukemia, Lymphoid / Q000150:complications / Q000188:drug therapy*; D008297:Male; D015122:Mercaptopurine / Q000494:pharmacology; D008657:Metabolic Clearance Rate / Q000187:drug effects; D008727:Methotrexate / Q000494:pharmacology; D010672:Phenytoin / Q000493:pharmacokinetics*; D011241:Prednisone / Q000494:pharmacology; D014750:Vincristine / Q000494:pharmacology
D014750:Vincristine; D010672:Phenytoin; D015122:Mercaptopurine; D011241:Prednisone; D008727:Methotrexate